FOR IMMEDIATE RELEASE VIRTUALSCOPICS, INC. PROMOTES RONALD WAY TO VICE PRESIDENT OF OPERATIONS ROCHESTER, N.Y. September 3, 2014-VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, today announced that Ronald Way, 59, has been promoted to vice president of operations. Mr. Way joined VirtualScopics in January 2011 as director of operations with responsibility for leading all the functions required to deliver clinical trial imaging solutions to the company's customers.

"Ron's promotion to vice president of operations is indicative of his significant knowledge of Lean Six Sigma methodologies as well as his strong team building and leadership capabilities that he has demonstrated on a daily basis since he joined the VirtualScopics' team over three years ago," said Eric T. Converse, president and chief executive officer. "Upon my arrival last October, every VirtualScopics employee with whom I spoke was quick to point out that it was Ron who led the team to vastly improved levels of imaging solutions deliveries and customer satisfaction ratings that the company has received since he took responsibility for project management, technical services, image processing and analysis, and site management."
"During my tenure at VirtualScopics, my focus has always been on our customers' needs," explained Mr. Way. "That means understanding their exact requirements for their clinical trial imaging assessments, being nimble and flexible to respond quickly to changes in protocols, and consistently producing the highest quality imaging solutions on time and within budget. I believe our capability to truly partner with our customers sets us apart from other clinical trial imaging providers and I'm proud of all we've accomplished together thus far."
Prior to working at VirtualScopics, Mr. Way spent 25 years as the director of manufacturing operations for Ultralife, Inc., a manufacturer of lithium battery systems for the military, medical and consumer markets. Mr. Way was responsible for the integration of all of the company's manufacturing operations in Texas, Mississippi and England, as well as the operational knowledge transfer to the company's facility in China.
Mr. Way attended the State University of New York at Brockport and has a B.S. degree in Business Management from the University of Phoenix. He received his Lean Six Sigma Black Belt Certification in 2009. Mr. Way is a recipient of the New York State Volunteer Service Award for his involvement in numerous youth activities over the years. Mr. Way resides in Canandaigua, New York, and enjoys spending time with his two children and four grandchildren.

About VirtualScopics, Inc.

VirtualScopics, Inc. (NASDAQ:VSCP) is a leading provider of clinical trial imaging solutions to
-more-

Imaging Solutions for Clinical Trials

500 Linden Oaks Second Floor Rochester, NY 14625 P:585.249.6231

F:585.218.7350mailto:info@virtualscopics.cominfo@virtualscopics.comfile:///C:/Users/tony_brognia/AppData/Local/Microsoft/Windows/AppData/Local/Microsoft/Windows/Temporary%20Internet%20Files/Content.IE5/AppData/Local/Microsoft/Windows/AppData/Local/Microsoft/Windows/Temporary%20Internet%20Files/Content.IE5/AppData/Local/Microsoft/Windows/AppData/Local/Microsoft/Windows/Documents%20and%20Settings/mark_tengowski/Application%20Data/Microsoft/Templates/www.virtualscopics.comwww.virtualscopics.com

VSCP Promotes Ronald Way to VP Operations, page 2

accelerate drug and medical device development. For risk-averse, time-constrained Clinical Trial Study Teams, Medical Directors and Imaging Scientists who require quality imaging data delivered on-time, within budget and on a consistent basis, VirtualScopics' clinical trial imaging solutions are an inspired true exception to commonly-accepted services provided by other clinical trial imaging providers. Because of the scientific and operational flexibility and responsiveness they can offer, VirtualScopics' clinical trial imaging solutions deliver special
performance advantages compared to other image service providers that offer common, everyday clinical trial imaging services. For more information about VirtualScopics, Inc., please visit www.virtualscopics.com.

Forward-looking Statements

The statements contained in this press release that are not purely historical are forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the company's investment in infrastructure, new office in New Hope, Pennsylvania, the Scientific Advisory Board, the strategic alliance with IXICO plc, the increase in awards outstanding and bookings and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans,"
"projects," "seeks," or similar expressions. Forward-looking statements deal with the company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward- looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the company's Annual Report on Form 10-K for the fiscal year ended December
31, 2013 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent Reports filed with the SEC, all of which are available at the SEC's website at http://www.sec.gov/www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contract awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risk of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release
and the company undertakes no obligation to update such forward-looking statements.

For More Information, Contact: Donna N. Stein, APR, Fellow PRSA Managing Partner

Donna Stein & Partners
315-361-4672
Email: mailto:dstein1@twcny.rr.comdstein1@twcny.rr.com
# # #

Imaging Solutions for Clinical Trials

500 Linden Oaks Second Floor Rochester, NY 14625 P:585.249.6231

F:585.218.7350mailto:info@virtualscopics.cominfo@virtualscopics.comfile:///C:/Users/tony_brognia/AppData/Local/Microsoft/Windows/AppData/Local/Microsoft/Windows/Temporary%20Internet%20Files/Content.IE5/AppData/Local/Microsoft/Windows/AppData/Local/Microsoft/Windows/Temporary%20Internet%20Files/Content.IE5/AppData/Local/Microsoft/Windows/AppData/Local/Microsoft/Windows/Documents%20and%20Settings/mark_tengowski/Application%20Data/Microsoft/Templates/www.virtualscopics.comwww.virtualscopics.com


!f
VIRTUALSCOPICS
Know more. Move (aster.

lmagmg Solulions for CllnlcalTnals

500 Linden Ooks Sec:ond Floor Rochesier,NV14625 P:585.249.6231

F:585.218.7350infp@

'irtualscopics.oom VlfliAlvirtualscopics.com

distributed by